Breakthrough therapies for the treatment of blood diseases
Our technology
A pressing issue affecting 1.1 million people in the US
HemoGenyx seeks to address the problems faced by tens of thousands of blood cancer patients that arise with Bone Marrow (BM) and Hematopoietic Stem Cell (HSC) Transplants, with their revolutionary treatments and therapies. Broad range of adverse side effects associated with current methods of conditioning patients for BM/HSC transplants – preventing many patients from receiving such treatment.
50%
High failure rate of BM/HSC transplants
>60K
Transplants are carried out annually worldwide
60%
Acute shortage of BM/HSC donors
Learn about the clinical need
A broad background in drug discovery and developing new drugs and navigating through the regulatory process
Our pipeline
A rich academic history at the base of our groundbreaking work
A rich academic history at the base of our groundbreaking work The company’s team has a broad background in developing new drugs and moving through the regulatory process. The company has been granted FDA orphan drug designation for its lead cell therapy product, the Hu-PHECs, to treat aplastic anaemia, enabling a faster route to commercialization, to get the therapies and treatments to patients most in need. The Company is seeking to expand the application to other blood diseases.
Find out more about us
Scientific excellence and a proven track-record are at the heart of our team
Our experienced team
Latest News
Mail Online
27 NOV, 2017
SMALL CAP SHARE IDEAS: PIONEERING BIOTECH FIRM HEMOGENYX SET TO TRANSFORM TREATMENT OF BLOOD CANCER
Born2Invest
20 NOV, 2017
A GLIMPSE AT THE GLOBAL BLOOD DISEASE MARKET
Keeping Stock
20 NOV, 2017
TOP 10 BIOTECH COMPANIES THAT ARE PUSHING THE ENVELOPE IN THE MEDICAL FIELD
A new era for the treatment of blood diseases
Our aim is to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy.